CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Glycopyrronium bromide

Last Updated: November 30, 2012
Result type: Reports
Project Number: SR0300-000
Product Line: Reimbursement Review

Generic Name: Glycopyrronium bromide

Brand Name: Seebri

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Therapeutic Area: Chronic obstructive pulmonary disease

Indications: Chronic Obstructive Pulmonary Disease (COPD), maintenance bronchodilator treatment

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 15, 2013

Recommendation Type: List with criteria/condition